Related Experiment Video
Updated: Jun 6, 2025
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
Relationship between liver and cardiometabolic health in type 1 diabetes
Emir Tas1,2, Bach-Mai Katherine Vu1,2, Brenda Mendizabal2,3
1Division of Endocrinology and Diabetes, University of Pittsburgh Medical Center (UPMC) Children's Hospital of Pittsburgh, Pittsburgh, PA, United States.
Insights
Metabolic dysfunction-associated steatotic liver disease (MASLD) significantly increases cardiovascular disease (CVD) risk in type 1 diabetes (T1D) patients. Early liver health assessment and management are crucial for mitigating CVD complications in this population.
Area of Science:
- Endocrinology
- Hepatology
- Cardiology
Background:
- Type 1 diabetes (T1D) is associated with increased cardiovascular disease (CVD) mortality.
- Traditional CVD risk factors do not fully explain the elevated risk in T1D.
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging factor in T1D-related CVD.
Purpose of the Study:
- To review the relationship between MASLD and CVD in individuals with T1D.
- To examine MASLD prevalence, risk factors, and impact on cardiovascular outcomes in T1D.
- To explore the mechanisms linking MASLD and CVD in T1D.
Main Methods:
- Narrative review of observational studies, cohort studies, and meta-analyses.
- Focused on literature investigating MASLD prevalence in T1D populations and its association with CVD.
- Examined physiological mechanisms including insulin resistance, inflammation, and hepatic dyslipidemia.
Main Results:
- MASLD is a significant contributor to CVD in T1D, especially with obesity and insulin resistance.
- MASLD exacerbates metabolic dysfunction, increasing CVD risk via inflammation and atherogenic lipids.
- Studies identified patterns in MASLD prevalence and its independent contribution to cardiovascular risk.
Conclusions:
- MASLD plays a critical role in heightened CVD risk among T1D patients.
- Targeting MASLD through liver health assessments and management is vital.
- Incorporating MASLD strategies into T1D care can mitigate long-term cardiovascular complications.
Introduction:
Type 1 diabetes (T1D) is a chronic condition marked by insulin deficiency and hyperglycemia, with an increasing global incidence, particularly among children. Despite improvements in diabetes management, individuals with T1D continue to experience higher rates of cardiovascular disease (CVD), the leading cause of mortality in this population. Traditional CVD risk factors such as dyslipidemia and poor glycemic control are insufficient to fully explain the elevated risk in T1D, prompting further investigation into additional factors. Emerging evidence suggests that metabolic dysfunction-associated steatotic liver disease (MASLD) plays a critical role in this heightened CVD risk.
Objective:
This narrative review aims to explore the relationship between MASLD and CVD in individuals with T1D. The review focuses on the prevalence of MASLD, its contributing risk factors, and the potential impact of liver dysfunction on cardiovascular outcomes in this population.
Methods:
A review of existing literature was conducted, focusing on observational studies, cohort studies, and meta-analyses that investigate the prevalence of MASLD in T1D populations and its association with CVD. The review also examines the physiological mechanisms linking MASLD and CVD, including insulin resistance, systemic inflammation, and hepatic dyslipidemia. Key studies were evaluated to identify patterns in MASLD prevalence based on diagnostic modalities and to assess the independent contribution of MASLD to cardiovascular risk in T1D patients.
Conclusion:
MASLD is increasingly recognized as a significant contributor to CVD in individuals with T1D, particularly in those with shared risk factors like obesity and insulin resistance. Evidence suggests that MASLD exacerbates hepatic and systemic metabolic dysfunction, increasing CVD risk through mechanisms such as chronic inflammation and atherogenic lipid profiles. Routine liver health assessments and tailored management strategies targeting MASLD should be incorporated into clinical care for individuals with T1D to mitigate long-term cardiovascular complications.
Related Concept Videos
01:36Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
01:19Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
01:22Diabetes Mellitus: Type 2 and Gestational
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:30Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...